William Tente MS
William (Bill) Tente is a seasoned biotechnology executive with over 40 years of experience in product development, regulatory affairs, and launching companies from academic spin-outs. He brings extensive expertise in advanced therapy medicinal products (ATMPs), including cell, gene, and tissue-engineered therapies.
Prior to joining Tiziana, Mr. Tente held senior roles at Humacyte Global, Inc., where he served as Chief Regulatory Officer and led the regulatory strategy for Symvess? (an acellular tissue-engineered vessel), securing landmark designations including the first FDA RMAT under the 21st Century Cures Act, Priority Review from the DoD, and Sakigake finalist status in Japan. He contributed to raising over $450M in private financings and a $230M+ IPO while overseeing pre-clinical, manufacturing, quality, and global clinical programs.
Earlier positions include Vice President of Operations at Neurotech USA (encapsulated cell therapies for retinal diseases), Director of Operations at Chimeric Therapies (bone marrow processing), and Director of Clinical Production at CytoTherapeutics (encapsulated cell therapies). At Ares Serono, Charles River, and Schering, he played key roles in developing three approved recombinant infertility products: Gonal-F?, Luveris?, and Ovidrel?.
Mr. Tente holds B.S. and M.S. degrees in cell biology and microbiology from the University of Rhode Island and studied at the W. Alton Jones Cell Sciences Center. He was a member of the USP Expert Committee on Gene Therapy, Cell Therapy, and Tissue Engineering (1997–2015), serving as Chairman from 2005–2010.